Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Nepean Dyspepsia Index Applies To Functional Dyspepsia In China
FD, a common non-organic disease in the world, greatly affects a patient"s quality of life. However, treatment of FD is still controversial and no single therapy is uniformly effective, due, in part, to absence of a reliable evaluation instrument. The Nepean Dyspepsia Index (NDI), measuring both symptom scores and impairment of the dyspepsia-specific health-related quality of life in FD patients, has been designed to diagnose FD and has been translated into several languages. Moreover, its utility has been proved to be validated by researches in western countries. However, DI has not been translated and validated in China.
generic viagra online
Two Types Of Urgency - Overactive Bladder - Urgency Is Not Just Urgency
UroToday.com - "Urgency" is the cornerstone of the diagnosis of overactive bladder (OAB) as well as a common complaint of patients with BPS/IC. What the term actually refers to when used by patients remains problematic and the subject of some controversy. The International Continence Society defines it as a "sudden compelling desire to void that is difficult to defer". The word sudden is designed to differentiate the sensation from the "urgency" that patients with BPS/IC complain of, but the distinction is quite vague in practice. Many believe that it is the reason for the urgency (fear of incontinence vs. pain) that should make the distinction.
News of the day
Access Pharmaceuticals Provides Update On ProLindac(TM) Phase 2 Ovarian Cancer Trial And Clinical Development Plan
ACCESS PHARMACEUTICALS, INC.(OTC Bulletin Board: ACCP), provided an update on the progress in the Company"s clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor types in human clinical studies. Access recently announced positive safety and efficacy results from its Phase 2 monotherapy clinical study of ProLindac(TM) in late-stage, heavily pretreated ovarian cancer patients. In this study, 66% of patients who received the highest dose achieved clinically meaningful disease stabilization according to RECIST criteria. No patient in any dose group exhibited any signs of acute neurotoxicity, which is a major adverse side-effect of the approved DACH platinum, Eloxatin, and ProLindac was well tolerated overall. The Company has scaled up manufacturing in order to begin the next phase of clinical development. Access plans to conduct several combination trials in different solid tumor types both as Company-sponsored trials and in conjunction with its two previously announced co-development partners.
Oncology

Published Study Shows VNUS ClosureFAST(TM) System Significantly Superior To Laser For Varicose Vein Treatment

VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS), a worldwide leader in medical devices for the minimally invasive treatment of venous reflux disease, announced that the Journal of Vascular & Interventional Radiology, the prestigious monthly publication of the Society of Interventional Radiology, has published a study showing the VNUS ClosureFAST(TM) system for radiofrequency (RF) thermal ablation to be "significantly superior" to endovenous laser (EVL) for treating venous reflux, the underlying cause of symptomatic varicose veins. The VNUS ClosureFAST catheter is a minimally invasive device generally used in the physician"s office with a local anesthetic to heat and seal the great saphenous vein, the most common site of venous reflux in the leg. The RECOVERY trial was a multicenter, randomized, single-blinded study of 87 vein ablation procedures in 69 patients, comparing the ClosureFAST radiofrequency catheter to the 980 nm endovenous laser system. The study found that for all primary endpoints in the trial, the ClosureFAST radiofrequency catheter was statistically superior to laser treatment in providing a fast and comfortable recovery for the patient after treatment. Specifically, radiofrequency vein ablation using the ClosureFAST catheter was shown to result in less postoperative pain, less bruising, less tenderness, and better reduction of symptoms than laser as soon as two days after treatment, and remaining considerably better for at least two weeks or longer. In addition, all statistical differences in postprocedural and quality-of-life parameters were superior in the ClosureFAST group, and minor complications were five times less prevalent. "The study found RF thermal ablation, as performed with the ClosureFAST catheter, superior to EVL as measured by a comprehensive array of postprocedural recovery and QOL comparisons between these two minimally invasive techniques for closure of the greater saphenous vein," said Jose I. Almeida, M.D., lead author of the study and Medical Director of Miami Vein Center. "The study confirms what many of us who have used both laser and radiofrequency devices have felt subjectively - that there is significantly enhanced patient comfort with the radiofrequency technology," said Raymond G. Makhoul, M.D., of Richmond, Virginia, a researcher for the study. "The ClosureFAST device clearly provided a superior patient experience." "This study emphatically supports the experience of our customers who frequently describe the ease of use of our ClosureFAST radiofrequency catheter and the rapid and mild recovery of patients treated with the catheter," said Brian E. Farley, President and CEO of VNUS. "The trial data also explains the enthusiastic adoption of our technology by the physician community. The publication of the RECOVERY Trial results complements other medical journal publications showing over 97% efficacy from the ClosureFAST catheter. Together with the positive endorsement from European national health authorities, we believe this therapy can be regarded as the premier technology for the treatment of venous reflux disease, a medical condition afflicting millions of people worldwide." ABOUT VNUS MEDICAL TECHNOLOGIES, INC. Founded in 1995 and headquartered in San Jose, California, VNUS Medical Technologies (NASDAQ: VNUS) is a worldwide leader in medical devices for the minimally invasive treatment of venous reflux disease, a progressive condition that is the underlying cause of varicose veins. VNUS sells the Closure system, which consists of a proprietary radiofrequency (RF) generator and proprietary disposable endovenous catheters and devices to treat diseased veins through the application of temperature-controlled RF energy. VNUS Medical Technologies, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009